




SCIENTIFIC DRUG AND ALCOHOL CONFERENCE

APSAD **ADELAIDE 2023**

'Unity in Diversity'

HANDBOOK



APSAD

The Australasian Professional Society
on Alcohol and other Drugs

Naa Marni – it's good you have come

Nestled between the picturesque Mount Lofty Ranges to the east, the Barossa Valley to the north, McLaren Vale to the south and Gulf St Vincent to the west, Adelaide/Tarndanya is the fifth most populous city in the country and was named Australia's most liveable city in 2021.

Once known as the City of Churches, Adelaide is now famous for being home to Wang Wang and Fu Ni, the only pandas living in Australia, as well as for its many festivals and events including WOMAD, the Adelaide Fringe Festival, the Cabaret Festival, the Adelaide 500 Supercar race, and most important of all, the 2023 APSAD Conference from 12-15 November 2023.

The venue, the Adelaide Convention Centre, overlooks the River Torrens in the heart of the CBD, a short walk from the cultural precinct of the Museum and Art Gallery, the shopping precinct of Rundle Mall, the Botanic Gardens and the Zoo, and the dining and entertainment precincts of Hindley and Gouger Streets.

Our theme for the 2023 conference is *Unity in Diversity*. This theme speaks to both the great diversity in our client groups including Aboriginal and Torres Strait Islander people, refugees, culturally and linguistically diverse people, and the LGBTQIA+ rainbow community; and also, to the crucial contributions of professionals from a range of backgrounds including researchers, public health professionals, policy makers, clinicians and peers, all with the common goal of improving outcomes for people who use alcohol and other drugs.

With seven fantastic keynote addresses, eleven symposia, seven workshops, over 200 oral presentations and over 100 posters, there is literally something for everyone! We are proud to welcome you to an exciting conference with a focus on inclusion and innovation in 2023.

Kate Senior & Vicky Cook



CONTENTS

Acknowledgements	05
Sponsors	06
Conference App Details	07
Keynote Speakers	10
James Rankin Oration	15
APSAD Awards Ceremony	18
Associated Events	20
Program Overview	22
Exhibitor Directory	26
Exhibition Floor Plan	29

Disclaimer

The views expressed by keynotes, oral presenters, poster presenters and speakers are not necessarily the views of APSAD, and the Society does not accept responsibility for any information, research, recommendation, or advice contained herein.

The views expressed by sponsors, exhibitors, advertisers, or attendees are not necessarily the views of APSAD, and the Society does not accept responsibility for any information, research, recommendation or advice contained herein.





ADELAIDE
CONVENTION
CENTRE

WELCOME TO ADELAIDE!

Adelaide Convention Centre is proud to support the APSAD Scientific Drug and Alcohol Conference 2023 and welcomes delegates to Adelaide, South Australia.

Ranked one of the world's safest, green and most liveable cities, Adelaide is a vibrant and innovative destination known for its world-class health and medical ecosystem.

Conveniently located next door to Adelaide BioMed City — the largest health and medical research precinct in the Southern Hemisphere — Adelaide Convention Centre puts people and experiences at the centre of business events. From sustainable practices to nutritionally balanced culinary creations, there's plenty to discover and enjoy in Adelaide, **Australia's Convention City.**



Adelaide, Australia's Convention City.
+ 61 8 8210 6677 | adelaidecc.com.au

Acknowledgement of Country

In the spirit of reconciliation, APSAD acknowledges the Traditional Custodians of Country throughout Australia and their connections to land, sea and community. In recognition that APSAD is a bi-national Society, we acknowledge Māori as tangata whenua and Treaty of Waitangi partners in Aotearoa New Zealand.

For this conference, APSAD specifically acknowledges the Kurna People of the Adelaide Plains as the Traditional Custodians of the lands upon which we meet. We pay our respects to their Elders past and present, and extend that respect to all First Nations people attending the conference.

Recognition of Lived Experience

APSAD recognises the lived experience of people living with alcohol & other drug use and mental illness, their families, carers, and support people. We respect and value their opinions and their input into research, teaching, service delivery and change.

Environmental Policy

APSAD along with ASHM Conference and Events Division implements a waste reduction policy that addresses:

- Reduce, Reuse, Recycle. This is done before, during and after each conference.
- APSAD along with ASHM Conference & Events Division reduces the number of printed materials by using electronic communication means wherever possible, including the website, email, online registration and abstract submission.
- APSAD along with ASHM Conference & Events Division monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste.
- APSAD along with ASHM Conference & Events Division aims to research and prioritise purchasing items and equipment that support the use of recycled materials or can be recycled after use.
- APSAD along with ASHM Conference & Events Division will aim to ensure that recycling bins are available onsite at all events.
- APSAD along with ASHM Conference & Events Division will endeavour to minimise travel through the use of teleconferences instead of face-to-face meetings and holding meetings only when necessary.

APSAD along with ASHM Conference & Events Division encourages all conference stakeholders to consider the environment by suggesting the following: reduction in printing requirements; recycling conference materials; and reusing conference merchandise.

Office details

ASHM National Office
A Level 3, 160 Clarence Street
Sydney, NSW, 2000
T +61 458 291 166
E apsadconference@ashm.org.au
W www.ashm.org.au

ABN: 48 264 545 457
CFN: 17788
© APSAD 2023
Design and layout by Coolamon Creative
Printed by TTR Print Management



SPONSORS

Platinum:

camurus®



Gold:



Government of South Australia
SA Health



Principal Partner:



CONFERENCE APP DETAILS

The conference app is the best way to stay informed during the conference. The best part is it's free to download from the Apple app store or Google Play!

What can I do with the app?

- Create your own agenda
- View the program by time or session, read the abstracts, make notes
- Answer polling questions during presentations
- Search for speakers, read their bio and see what presentations they are giving
- View a list of all the sponsors and exhibitors and find out which booths they are at
- Send a direct message to that person you have been trying to pin down for a meeting

How do I get the app?

The Conference App is available to download from the Apple app store or Google Play. Simply search for 'Events App by EventsAIR'.

Google Play QR Code:



iOS QR Code:



How do I login to the app?

Once you have found the app in your App Store:

1. Install the App.
2. The first time you open the app, you will need to enter the event code: APSAD23
3. To login, enter your primary email address and pin located on the back of your name badge.
4. You are all set! If you have any questions visit the conference team located at the Registration desk!



TWITTER

We will be using Twitter during the Conference for discussion and questions. The hashtag we will be using is: **#APSAD23**



Weekly/Monthly
Buvidal[®]

BUPRENORPHINE

MODIFIED RELEASE SOLUTION FOR
INJECTION FOR SUBCUTANEOUS USE

**FREEDOM
TO
CHOOSE^{1,2}**



 Choose direct initiation with Buvidal[®] Weekly¹

 Choose between Weekly or Monthly maintenance dosing^{1,2}

 Choose from a range of doses^{1,2}

 Choose from eight injection sites^{1,2}

For the treatment of opioid dependence^{1,2}

VISIT [BUVIDAL.COM.AU](https://www.buvidal.com.au) FOR MORE INFORMATION

PLEASE REVIEW THE BUVIDAL® WEEKLY AND BUVIDAL® MONTHLY PRODUCT INFORMATION BEFORE PRESCRIBING. PRODUCT INFORMATION IS AVAILABLE BY CALLING 1800 142 038

PBS INFORMATION: S100 [HSD] listing. Authority Required (STREAMLINED). Opioid Dependence. Refer to PBS Schedule for full Authority Required Information.

Please note that Buvidal® prescribing must comply with State and Federal regulations for opioids

WARNINGS: Risk of Serious Harm or Death with Intravenous Administration: Serious harm or death could result if administered intravenously. Buvidal® forms a gel depot upon contact with body fluids and may cause occlusion, local tissue damage and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously. Additional warnings are associated with **Hazardous and harmful use, Life threatening respiratory depression, Concomitant use of benzodiazepines and other central nervous system (CNS) depressants, including alcohol.** Please refer to the Buvidal® Weekly and Buvidal® Monthly Product Information for the full boxed warning.

MINIMUM PRODUCT INFORMATION: Buvidal® Weekly (8 mg, 16 mg, 24 mg and 32 mg) and Buvidal® Monthly (64 mg, 96 mg, 128 mg and 160 mg) buprenorphine modified release solution for injection. **Indication:** Buvidal® Weekly is indicated for initiation and maintenance treatment of opioid dependence, with or without prior stabilisation on sublingual buprenorphine or buprenorphine/naloxone, within a framework of medical, social and psychological support. Buvidal® Monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on Buvidal® Weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support. **Contraindications:** hypersensitivity to buprenorphine or any excipients; children <16 years; severe respiratory or hepatic insufficiency (Child-Pugh C); acute alcoholism or delirium tremens. **Precautions:** concomitant use of opioids with benzodiazepines, gabapentinoids, antihistamines, tricyclic antidepressants, antipsychotics, cannabis or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death; incorrect route of administration; risk of serious harm or death with intravenous injection; orthostatic hypotension; head injury; intracranial lesions; history of seizure; prostatic hypertrophy; urethral stenosis; myxoedema; hypothyroidism; adrenal cortical insufficiency; dysfunction of the biliary tract; elderly or debilitated patients; misuse, abuse and diversion; respiratory insufficiency; risk of dependence and withdrawal; neonatal abstinence syndrome; moderate hepatic impairment or severe renal impairment; allergic reactions; use in pregnancy (Category C) and lactation; driving and operating machinery. **Interactions:** benzodiazepines, gabapentinoids, alcohol, CNS depressants, opioid analgesics, naltrexone, nalmeferene, CYP3A4 inhibitors and inducers, MAO inhibitors, serotonergic medicines. **Adverse Effects:** administration site conditions (injection site pain, pruritis, erythema, swelling, reaction, induration or mass), nausea, vomiting, diarrhoea, constipation, toothache, tooth abscess, pyrexia, cough, nasal congestion, nasopharyngitis, upper respiratory tract infection, urinary tract infection, ear pain, oral herpes, tachycardia, laceration, alanine aminotransferase increased, aspartate aminotransferase increased, weight decreased, arthralgia, back pain, muscle spasms, neck pain, pain in extremity, headache, dizziness, hypoaesthesia, anxiety, insomnia, depression. **Dosage and administration:** Buvidal® is given by subcutaneous injection and administration is restricted to healthcare professionals. Buvidal® is indicated for individualised therapy across treatment phases from initiation and stabilisation to maintenance treatment. See full PI for dosing information when transitioning patients from short-acting opioids, methadone or sublingual buprenorphine as well as transitioning patients between Buvidal® Weekly and Buvidal® Monthly. Maximum dose of Buvidal® Weekly treatment is 32 mg with an additional 8 mg dose. Maximum dose of Buvidal® Monthly treatment is 160mg. Based on Approved PI: 17 Jan 2023.

References: 1. Buvidal® Weekly Australian Approved Product Information January 2023. 2. Buvidal® Monthly Australian Approved Product Information January 2023.

camurus

Buvidal® is the registered trademark of Camurus AB. Camurus Pty Ltd. ABN 79 627 784 605. 223 Liverpool Street, Darlinghurst NSW 2010. Ph: 1800 142038. AU-BUV-2300030. CAM-BUV-79. Date of preparation: July 2023.

KEYNOTE SPEAKERS



Chris Bullen

I am a New Zealander of British and Polish descent, with strong roots in Aotearoa New Zealand. I work as a Professor in Public Health at the School of Population Health, University of Auckland, where I am the Academic Director of the National Institute for Health Innovation, a member of the Centre for Addiction Research and Centre for Heart Health. I trained as a physician, and after a decade in clinical practice mostly in Papua New Guinea, trained as a public health medicine specialist. My group's research generally involves large pragmatic clinical trials of affordable and scalable interventions. We have shown the effectiveness of smoking cessation interventions such as text messaging, pre-quitting nicotine replacement therapy, e-cigarettes, cytisine, and reducing nicotine content in cigarettes. I have published over 250 peer-reviewed articles and am President of the Society for Research on Nicotine and Tobacco.



Chris Gough

Chris Gough is the Executive Director of the Canberra Alliance for Harm Minimisation and Advocacy (CAHMA) and The Connection health service and is the President of the Board of the Australian Illicit and Injecting Drug Users League (AIVL). He identifies as a person who uses drugs and Chris' expertise centres around peer and consumer driven programming including peer education, peer treatment support, community development, consumer representation and advocacy.



Nicole Hewlett

Nicole Hewlett is a proud palawa woman from lutruwita (Tasmania) with over 14 years of demonstrated knowledge translation experience working in Aboriginal and/or Torres Strait Islander public health around Fetal Alcohol Spectrum Disorder (FASD), justice, alcohol policy, palliative care and wellbeing. Nicole is currently undertaking a PhD, holds two positions with University of Queensland, and during 2018-2023, was a board member and Treasurer of the National Organisation for Fetal Alcohol Spectrum Disorders (NOFASD). At The University of Queensland, Nicole works in the First Nations Cancer and Research Wellbeing Program as well as at the Child Health Research Centre to embed Aboriginal healing-informed, strengths-based and culturally responsive practices into Australia's revised Guidelines for the Assessment and Diagnosis of FASD. From 2016 – 2021, Nicole was a committee member of the NHMRC Alcohol Working Group, appointed to update Australia's alcohol drinking guidelines.



Beau Kilmer

Beau Kilmer (he/him) is the McCauley Chair in Drug Policy Innovation, codirector of the RAND Drug Policy Research Center, and a senior policy researcher at the RAND Corporation. He is also a Professor of Policy Analysis at the Pardee RAND Graduate School and the Vice President of the International Society for the Study of Drug Policy. His research lies at the intersection of public health and public safety, with special emphasis on crime control, substance use, illegal markets, and public policy.

Some of his recent projects include assessing the consequences of cannabis legalization (with a special focus on social equity); measuring the effect of 24/7 Sobriety programs on impaired driving, domestic violence, and mortality; facilitating San Francisco's Drug Dealing Task Force; analyzing changes in illegal fentanyl markets; and evaluating the evidence and arguments made about heroin-assisted treatment and supervised consumption sites.

Kilmer's publications have appeared in leading journals such as *New England Journal of Medicine* and *Proceedings of the National Academy of Sciences*, and his commentaries have been published by CNN, Los Angeles Times, New York Times, San Francisco Chronicle, USA Today, Wall Street Journal, and other outlets. His coauthored book on cannabis legalization was published by Oxford University Press and his coauthored book on the future of fentanyl and other synthetic opioids was published by RAND. He received his Ph.D. in public policy from Harvard University, M.P.P. from UC-Berkeley, and B.A. from Michigan State University.



Rebecca McKetin

Associate Professor Rebecca McKetin (BSc(Psychol)Hons. PhD) leads a program of research into stimulant use epidemiology and interventions at the National Drug and Alcohol Research Centre, UNSW. Rebecca's current aspiration is to develop and disseminate effective treatment and harm reduction options for people using methamphetamine. Her work includes developing and evaluating online psychological self-help tools, pharmacotherapy trials and evaluating community-based treatment options. She is passionate about improving the coverage of treatment and other health services for people who use methamphetamine, and she has also done much research to help understand the relationship between methamphetamine use and mental health outcomes. Rebecca has consulted to the United Nations; she is a former NSW/ACT Young Tall Poppy, a Senior Editor for *Addiction*, a member of the UNSW Academic Board, and a member of the Australian Institute of Policy and Science.



Suzanne Nielsen

Professor Suzanne (Suzi) Nielsen is the Deputy Director of the Monash Addiction Research Centre. She has published > 180 peer-reviewed publications in the alcohol and other drugs field. She has been a registered pharmacist for over 20 years, specialising in the treatment of substance use disorders in community and specialist drug treatment settings in Australia and the United Kingdom.

Her current research focuses on upscaling opioid treatment and overdose prevention, and on understanding the impact of opioid policy on prescribing and opioid-related harm. Her work has directly contributed to changed policy (for example, the rescheduling of codeine) and practice (for example, increased pharmacy naloxone supply).

Suzi holds honorary appointments at the Burnet Institute, Turning Point, UNSW and Alfred Health, and is a consultant for the World Health Organization contributing to the work of the Expert Committee on Drug Dependence and international surveillance of emerging substances.



Anna Olsen

Dr Olsen is Associate Professor of Social Foundations of Medicine at the ANU Medical School. Her interdisciplinary program of research combines practical and critical approaches to public health, with a particular interest in marginalised populations and qualitative methodologies. Current research includes: drug checking; opioid overdose prevention; drug use and motherhood; domestic and family violence; Aboriginal and Torres Strait Islander Health; and ethical practice in social research. She values collaborative approaches to research and has extensive experience working with government and community on evaluation and research projects.



Alison Beck

Dr Alison Beck is an Early Career Researcher and Clinical Psychologist. She works part-time at the University of Wollongong as a Postdoctoral Research Fellow in Meaningful Outcomes, an NHMRC CRE focused on substance use treatment and part-time in clinical practice at a therapeutic community. Alison's research is focused on improving the quality of treatment for people who use alcohol and other drugs. She has a special interest in mutual help groups and treatment fidelity.



Sara Farnbach

Sara is a Registered Nurse, early career researcher and Program Lead, RISE Team (Research, Innovate, Strengthen, Embed) at the National Drug and Alcohol Research Centre, UNSW. She is passionate about improving the health and wellbeing of priority populations through combining co-design with research methods to plan, implement and evaluate programs and services that are highly acceptable and effective. Her program is focused on working collaboratively with communities in rural and regional NSW to tailor health services and health initiatives to their setting. Her PhD research focused on facilitators to conducting high-quality and culturally-appropriate research in partnership with Aboriginal and Torres Strait Islander communities. She has research experience working on qualitative designs, embedding evaluations into service delivery and RCTs. She has an interest in novel approaches to service evaluation, using routinely collected data and pragmatic trial designs. She has a Masters of Public Health and Tropical Medicine and has worked in the Philippines and the Pacific on several programs including communicable disease control and maternal and child health. She has also worked on health promotion programs in Australia.





Scott Wilson (James Rankin Orator)


Scott Wilson is a well-respected Aboriginal leader and CEO of the Aboriginal Drug and Alcohol Council (South Australia (ADAC) for over 30 years.). He is also an Adjunct Associate Professor in the Faculty of Medicine and Health at the University of Sydney. His other past leadership roles include being Deputy Chair of both the National Indigenous Drug and Alcohol Committee and the Alcohol Education Rehabilitation Foundation (FARE).

Scott's personal and professional experience in substance misuse has made him a valued member of nearly every major governmental and non-governmental committee in Australia for more than 30 years. He has received several awards including the Australian Centenary Medal and the Sister Alison Bush Award from the University of Sydney.

Scott is also the Lead Convener of the South Australian Aboriginal Community Controlled Organisation Network (SAACCON), and represents not only the specific needs of the SA Aboriginal community, but our NFP organisations at the National level, through the National Aboriginal Community Controlled Organisation of Peaks (Coalition of Peaks), of which he is the Deputy Lead Convenor. The CoP is made up of 80 Peak Aboriginal and Torres Strait Islander Organisations from across Australia.



JAMES RANKIN ORATION



The James Rankin Oration is an annual oration which has been held during the APSAD Conference since 1990 and is named in honour APSAD's first President and co-founder Professor James (Jim) Rankin. Professor Rankin established the first medically-based combined clinical and academic program for the treatment and of study for alcohol in Australia at St Vincent's Hospital in Melbourne in 1964. When St Vincent's Hospital, Sydney established the new building for Drug and Alcohol Services, it was named 'Rankin Court' in recognition of Jim's assistance in establishing the services.

The James Rankin Oration honours a significant Australasian contributor to research, practice, and policy in alcohol, tobacco, and other drugs.


To learn more about James Rankin and to see the honours list of James Rankin Orators visit the APSAD website.

TURN TO HELP


Supporting those with opioid dependence at **every step** of their journey

Visit Turn to Help for information on opioid dependence, how to overcome it and where to find a doctor.

www.turntohelp.com.au



Indivior Pty Ltd, ABN 22 169 280 102. 78 Waterloo Road,
Macquarie Park, NSW 2113.
NP-GEN-AU-00119. August 2022. IND2025.





APSAD

Awards Ceremony

Presentation 1

Mentor Award, Senior Scientist Award

Date: Monday 13 November

Time: 2:30pm

Location: Hall L

Presentation 2

Mid Career Award, First Peoples Award

Date: Tuesday 14 November

Time: 9:35am

Location: Hall L

Presentation 3

Early Career Award, Clinician Award, Advocacy Award

Date: Wednesday 15 November

Time: 11:45am

Location: Hall L



APSAD AWARDS FOR EXCELLENCE IN SCIENCE RESEARCH AND PRACTICE

APSAD Awards for excellence in Science Research & Practice

As Australia's leading multidisciplinary organisation for professionals involved in the drug and alcohol field, these prestigious Awards are our unique celebration of the outstanding efforts and achievements of the individuals and teams who provide devoted and unstinting service to their communities in diverse fields and go unrecognised.

Acknowledging dedication and excellence in our sector is a key part of the APSAD Awards, as well as encouraging future generations of great researchers and clinicians.

The Awards are nominated by APSAD's members and decided by the APSAD Awards Committee.

Recipients of the APSAD Awards are recognised as having made an outstanding contribution to reducing the harms associated with alcohol and other drug use in Australasia. All seven Awards reflect excellence in the application of theory and knowledge to any aspect of drug and alcohol use. The Awards are designed to:

- Acknowledge significant contributions to alcohol, tobacco, and other drugs science, practice, and mentorship
- Recognise and support young scientists with exceptional potential Provide role models for the future generations of Australian alcohol, tobacco, and other drugs scientists and clinicians.

The 2022 APSAD Advocacy Awardee, NUAA will be delivering their Advocacy Workshop on

Monday 13 November 11:40 – 12:40 in Session 1C

ASSOCIATED EVENTS

APSAD WELCOME RECEPTION

Date: Monday 13 November

Time: 5:40pm

Location: Exhibition Hall

Held at the Convention Center the APSAD Welcome Networking Event is an opportunity to network with your peers whilst enjoying canapes.

Must have a ticket to attend.

APSAD EARLY-TO-MID CAREER RESEARCHERS NETWORKING BREAKFAST

Date: Tuesday 14 November

Time: 7:30am

Location: Riverbank Room 8

The APSAD Early-Mid Career Researchers (EMCR) Networking Breakfast is an excellent opportunity to network with other EMCRs and senior researchers and hear invited speakers discuss a priority topic selected based on feedback from APSAD EMCRs.

Must have a ticket to attend.

Sponsored by:



APSAD CONFERENCE DINNER

Date: Tuesday 14 November

Time: 7:00pm

Location: South Australian Museum

Join us at the South Australian Museum for the APSAD 2023 Conference Dinner. This year's dinner is a stand-up cocktail dinner with substantial canapes and soft drinks, a cash bar will be in operation. Fusing heritage architecture and contemporary design, mingle beneath a canopy of sculptures and experience the exhibits of the Museum.

Must have a ticket to attend.

CAMURUS SPONSORED SYMPOSIUM

Date: Tuesday 14 November

Time: Arrival and breakfast: 7:00am

Panel Discussion: 7:30 - 8:30am

Location: Riverbank Room 5

Camurus invite all registered healthcare professionals attending APSAD 2023, to join a panel of Australian experts including Professor Paul Haber (Sydney University, Clinical Director Drug Health Services Royal Prince Alfred Hospital), Paul Dessauer (CEO Peer Based Harm Reduction WA), Doctor Deborah Zador (Sydney University, Chief Addiction Specialist at the Centre for Alcohol and other Drugs) and Associate Professor Mark Daghli (University of Qld, Director of Addiction Psychiatry Royal Brisbane and Women's Hospital and Director of HADS) who will discuss the topic '**Long Acting Injectable Buprenorphine (LAIB) - have we got it right? Reflections from consumers, clinicians and policy-makers**'.



PROGRAM OVERVIEW

SUNDAY 12 NOVEMBER 2023			
12:00 - 6:00	9:30 - 2:30	9:00 - 1:00	9:00 - 4:00
NCCRED Symposium Riverbank Room 5	Smoking Cessation Update Day Pre-Conference Workshop Riverbank Room 6	Causal Inference in Addiction Research Pre-Conference Workshop Riverbank Room 7	The Fetal Alcohol Spectrum Disorder Special Interest Group (FASD SIG) Pre- Conference Workshop Riverbank Room 8

MONDAY 13 NOVEMBER 2023

08:30 - 10:20	Opening Plenary Session Chair: Kate Senior Room: Hall L					
10:20 - 10:50	Morning Tea Room: Exhibition Hall	Concurrent Session 1A SUBSTANCE USE IN PREGNANCY & PARENTS Chair: Nicole Hewlett Room: Hall L	Concurrent Session 1B LGBTIQ+ Chair: Bianca Davidde Room: Riverbank 6	Concurrent Session 1C PSYCHEDELICS + 2022 APSA ADVOCACY AWARD WORKSHOP Chair: Michael White Room: Riverbank 7	Concurrent Session 1D NEW TECHNOLOGIES & e-INTERVENTION + TREATMENT & INTERVENTIONS Chairs: Katherine Conigrave & Jimmy Perry + Peter Kelly Room: Riverbank 8	Concurrent Session 1E ALCOHOL & WOMEN Chair: Vicky Cock Room: Riverbank 4
12:40 - 13:40	Lunch Room: Exhibition Hall					
13:40 - 15:25	Afternoon Plenary Session Chair: Anke van der Sterren Room: Hall L					
15:25 - 15:50	Afternoon Tea Room: Exhibition Hall					
15:50 - 17:30	Concurrent Session 2A TREATMENT SETTINGS + TRANSLATION TO POLICY & PRACTICE Chair: Leanne Hides + Suzie Hudson Room: Hall L	Concurrent Session 2B MEDICALLY SAFE INJECTING FACILITIES + CRIME & JUSTICE Chair: Kate Senior Room: Riverbank 6	Concurrent Session 2C POLICY REFORM Chair: TBC Room: Riverbank 7	Concurrent Session 2D YOUTH Chair: Amy Peacock Room: Riverbank 8	Concurrent Session 1E WORKFORCE + GAMBLING Chair: David Newcombe Room: Riverbank 4	
17:35 - 18:35	Drug & Alcohol Review Editorial Board Meeting Invitation Only Room: Riverbank 5					
17:40 - 19:00	Welcome Reception must have a ticket to attend Room: Exhibition Hall					
19:00 - 20:30	2023 Friends of the Review Event Invitation Only Room: Gilbert Room					

07:15 - 08:40

Early-to-Mid Career Researcher Networking Breakfast

Room: Riverbank 8 - **must have a ticket to attend**

Camurus Symposium Breakfast - Long Acting Injectable Buprenorphine (LAIB) - have we got it right? Reflections from consumers, clinicians and policy-makers
Room: Riverbank 5 - **must have a ticket to attend**

08:40 - 10:40

Morning Plenary Session | Chair: Leanne Hides | Room: Hall L

10:40 - 11:10

Morning Tea

11:10 - 12:45

Concurrent Session 3A

SMOKING & VAPING
Chair: Janni Leung
Room: Hall L

Concurrent Session 3B

METHAMPHETAMINE
Chair: David Newcombe
Room: Riverbank 6

Concurrent Session 3C

EPIDEMIOLOGY
Chair: Chris Holmwood
Room: Riverbank 7

Concurrent Session 3D

PEERS & WORKFORCE ISSUES
Chair: Elisabeth Yarbakhsh
Room: Riverbank 8

12:45 - 13:45

Lunch | Room: Exhibition Hall

13:45 - 15:05

Afternoon Plenary Session | Chair: Michael White | Room: Hall L

15:05 - 15:50

Poster Tours and Poster Viewing Session | Room: Exhibition Hall

15:05 - 15:50

Afternoon Tea | Room: Exhibition Hall

Concurrent Session 4A - Part 1

INJECTABLE OPIOID TREATMENT
Chair: Alison Ritter
Room: Hall L

Concurrent Session 4B

FIRST NATIONS SMOKING CESSATION + DRUG POLICY & REFORMS
Chairs: Gina La Hera Fuentes & Kym Yuke + Melanie Walker
Room: Riverbank 6

Concurrent Session 4C

ALCOHOL
Chair: Jacquie Bowden
Room: Riverbank 7

Concurrent Session 4D

TREATMENT SETTINGS
Chair: Michael White
Room: Riverbank 8

Concurrent Session 4A - Part 2

SAFER SUPPLY
Chair: Suzi Nielsen
Room: Hall L

17:35 - 18:35

APSAD Annual General Meeting - APSAD Members Only | Room: Hall L

19:00 - 22:00

APSAD 2023 Conference Gala Dinner | Venue: South Australia Museum - **must have a ticket to attend**

WEDNESDAY 15 NOVEMBER 2023

08:45 - 10:00	Concurrent Session 5A OPIOID AGONIST TREATMENT Chair: Anke van der Sterren Room: Hall L	Concurrent Session 5B DRUG MONITORING Chair: Jeff Buckley Room: Riverbank 6	Concurrent Session 5C TREATMENT & INTERVENTIONS Chair: Jimmy Perry Room: Riverbank 7	Concurrent Session 5D CLINICAL TOOLKIT Chair: Michelle Taylor Room: Riverbank 8
10:05 - 10:35	Late Breakers Session 2 Chair: Craig Rodgers Room: Hall L			
10:35 - 11:00	Morning Tea Room: Exhibition Hall			
10:05 - 10:35	Morning Plenary Chair: Nathan Harrison Room: Hall L			
12:50 - 13:45	Lunch Room: Exhibition Hall			
13:45 - 15:20	Concurrent Session 6A DIVERSE POPULATIONS Chair: Elisabeth Yarbakhsh Room: Hall L	Concurrent Session 6B TREATMENT & INTERVENTIONS Chair: Sam Raven Room: Riverbank 6	Concurrent Session 6C INJECTING DRUG USE Chair: Vicky Cook Room: Riverbank 7	Concurrent Session 6D SCIENTIFIC PUBLISHING + JUSTICE DIVERSION Chair: Paul Dietze + Cassandra Wright Room: Riverbank 8
15:20 - 15:45	Afternoon Tea Room: Exhibition Hall			
15:45 - 16:35	Concurrent Session 7A COLLABORATIVE TREATMENT Chair: Craig Rodgers Room: Hall L	Concurrent Session 7B HARM REDUCTION Chair: TBC Room: Riverbank 6	Concurrent Session 7C OTHER PEOPLE'S AOD USE Chair: Jacquie Bowden Room: Riverbank 7	Concurrent Session 7D AGING POPULATION & CARE Chair: Kate Senior Room: Riverbank 8
16:40 - 17:05	Closing Plenary Session Chair: Kate Senior Room: Hall M			

EXHIBITOR DIRECTORY

BOOTH #



AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

1

AbbVie's commitment to eliminating the hepatitis C virus (HCV) goes beyond medicine. Today, people with HCV are harder to reach and many live among marginalised communities. By concentrating our efforts, sharing learnings and scaling what works, we aim to find sustainable solutions that will move us closer to a world free of HCV.

For more information about AbbVie, please visit us at www.abbvie.com.au. Follow @abbvie_AU on Twitter, Facebook, Instagram or our LinkedIn page.



APSAD is the leading multidisciplinary organisation bringing together professionals involved in the alcohol and other drugs field in Australasia. APSAD is dedicated to promoting evidence-based research, the translation of research into policy and practice, and best-practice, in treatment, prevention, and support related to alcohol, tobacco, and other drugs.

2

The society fosters collaboration among researchers, clinicians, policymakers, and other professionals working in this field to advance knowledge, share expertise, and contribute to better outcomes for individuals and communities affected by substance use issues. APSAD provides a platform for networking, education, and support, and driving advancements in the alcohol and other drugs field in the region.



Government of South Australia
SA Health



DASSA's strategic intention is the prevention and management of alcohol, tobacco and other drug-related issues across South Australia.

3

To achieve this, DASSA:

advises on a whole-of-government approach to prevent the use of illicit drugs and the misuse of licit drugs

- advises on policy relating to tobacco, alcohol and other drugs, and provides expert advice and support to SA's role in national policy development
- provides or brokers a range of prevention, intervention and treatment programs across the State with a particular focus on vulnerable, marginalised and high risk groups and behaviours
- advises on evidence-based practice, and
- participates in research.



The Drug and Alcohol Nurses of Australasia (DANA) is the leading organisation in Australasia for nurses, nurse practitioners, and midwives interested in Alcohol and Other Drug (AOD) issues. DANA promotes collaborative partnerships to achieve common goals and provides professional

4

development, education, mentoring, and support to its members. It aims to enhance the capacity of healthcare professionals to respond effectively and in a culturally sensitive manner to AOD issues. DANA offers guidance to stakeholders on AOD matters and related policies and also provides consultancy, advice, and advocacy on AOD issues, including promoting the inclusion of AOD issues in educational curricula and professional development programs.

4



The Tina Trial is a phase 3 randomised placebo-controlled trial of mirtazapine for methamphetamine use disorder. It is being led by NDARC, UNSW, in collaboration with academic institutions and frontline health services around Australia. The trial has been funded by the MRFF. Further information can be found at tinatrial.info.

5



The Guidelines on co-occurring conditions provide evidence-based information and training on the management of co-occurring alcohol and other drug and mental health conditions. Funded by the Australian Government Department of Health and Aged Care, all resources are freely available via comorbidityguidelines.org.au

6



Indivior is the world leader in addiction treatment with over 20 years' experience and a unique patient-focused approach. Our endeavour is to understand the journey of individuals suffering with addiction.

7 & 8

We partner with healthcare professionals, the public, policymakers, and payers to ensure people suffering from addiction are treated just like any other patients suffering from a chronic, relapsing medical condition.



NCETA is an internationally recognised research and knowledge translation centre that works as a catalyst for change in the AOD field. We work across the AOD continuum, from prevention through to treatment, with a key focus on workforce development. NCETA offers information and access to a range of AOD resources.

9



Insight and Dovetail are specialist providers of alcohol and other drug training, education, clinical resources and practice advice for workers and services. Our aim is to build a capable, confident and connected alcohol and other drug and mental health workforce.

10



For more than 30 years, Apothicom has been dedicated to the development of harm reduction supplies for people who inject drugs and to promoting safer injection practices. Based on field observations, tools like Stericup® cookers and Sterifilt® filters were designed and are distributed in many countries by harm reduction programmes.

11



Sana Health Group is a private provider in behavioural health, offering residential and day program treatment for addiction and mental health. Treatment is whole of person including a multidisciplinary team of medical, allied health, and qualified therapists. Sana's services currently include The Banyans, Byron Private, and Palladium Private.

12



Camurus is a Swedish research-based pharmaceutical company committed to developing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products are conceived based on the proprietary lipid-based FluidCrystal® drug delivery technologies and an extensive research and development expertise.

13 & 14

Camurus Australia's focus is on opioid dependence, with the aim of simplifying treatment and removing the burden and stigma for patients and their families.

If you wish to learn more about opioid dependence, visit: <https://www.camurus.com.au/opioiddependence/>



**Hunter New England
Local Health District**

Hunter New England Local Health District is one of the largest and most comprehensive health services in Australia, providing public health services to the Hunter, New England and Lower Mid North Coast regions of New South Wales. With a dedication to

15

Excellence – Every Patient, Every Time – staff are dedicated to make a genuine difference to the health and wellbeing of the communities they serve.



Biomed is a well established pharmaceutical manufacturer that has supplied methadone solution to the Australian opiate substitution program since 1998. We are a specialist manufacturer of intravenous and oral medications, particularly opiate active ingredients. Our methadone solution, Biodone Forte, is a sugar free formulation without alcohol and preservatives, in support of harm minimisation.

16



Alcoholics Anonymous is a fellowship of people who share their experience, strength and hope with each other, that they may solve their common problem and help others to recover from alcoholism. The only requirement for membership is a desire to stop drinking. There are no dues or fees for AA membership; we are self-supporting through our own contributions.

TT1


AA is not allied with any sect, denomination, politics, organization or institution; does not wish to engage in any controversy; neither endorses nor opposes any causes. Our primary purpose is to stay sober and help other alcoholics to achieve sobriety.



The Australian Indigenous Knowledge Centre's website contributes to improving the health of Australia's Aboriginal and Torres Strait Islander peoples and assist in closing the gap by providing the evidence base to help reduce the harmful use of alcohol and other drugs <https://aodknowledgecentre.ecu.edu.au/>

TT2

EXHIBITION FLOOR PLAN



Drug and Alcohol Services South Australia

Drug and Alcohol Services South Australia (DASSA) is a state-wide health service that offers a range of prevention, treatment and information services for people with alcohol, tobacco and other drug issues for the people of South Australia.

DASSA's strategic intention is the prevention and management of alcohol, tobacco and other drug-related issues across South Australia.

DASSA:

- advises on a whole-of-government approach to prevent the use of illicit drugs and the misuse of licit drugs
- advises on policy relating to tobacco, alcohol and other drugs, and provides expert advice and support to SA's role in national policy development
- provides or brokers a range of prevention, intervention and treatment programs across the State with a particular focus on vulnerable, marginalised and high risk groups and behaviours
- advises on evidence-based practice, and
- participates in research.

DASSA is accredited by the National Safety and Quality Health Service Standards. The Woolshed, DASSA's residential therapeutic community, which is based in the Adelaide Hills, is accredited by the Australasian Therapeutic Communities Association (ATCA).



Government of South Australia
SA Health

DRUG | **ALCOHOL** | **SERVICES**
SOUTH AUSTRALIA

JOIN APSAD



Be engaged and involved in a multidisciplinary professional society, gaining access to unique opportunities to broaden your knowledge across the AOD sector, network with colleagues, and fuel your passion for collaboration.

Networking and Collaboration: Connect with a diverse network of professionals in the AOD sector from researchers, policy makers, and clinicians. Build relationships, exchange ideas, and collaborate on projects with like-minded individuals from various sectors and disciplines.

Multidisciplinary AOD Conferences and Events: Receive exclusive registration fees and discounts to the annual APSAD conference, annual state-based symposia, workshops, webinars, and events with partnership organisations (DANA). Engage in thought-provoking discussions, share your insights, and gain fresh perspectives from professionals across the AOD sector. These events provide a platform to showcase your work and network.

Scholarship Grants and Funding: APSAD is committed to supporting rural/remote workers, frontline workers, students, and early-to-mid career researchers. As a member, you have the opportunity to apply for travel scholarships and funding to attend the annual conference or annual symposium.

Awards and Recognition: Celebrate your achievements, or a colleagues and receive well-deserved acknowledgment from your peers through our distinguished annual APSAD Awards for Excellence in Science, Research, and Practice, conference presentation awards, and recognition programs.

Engagement: Join an existing special interest group, or start a new member-led special interest group to connect with members who have similar interests. Join a subcommittee and assist with developing the society's position papers, policies, and advocacy.

Publication: Receive free access to the APSAD journal via the website or app. Share your expertise and research findings with a diverse audience. Contribute articles to the society's journal, and newsletters.

Mentorship Opportunities: Access mentorship opportunities designed to nurture your professional growth. Connect with professionals who can guide you on your career path, provide invaluable advice, and help you overcome challenges. Take advantage of career development resources, job boards, and opportunities within our network.

Knowledge Sharing and Learning: Stay ahead of the curve with access to cutting-edge, evidence-based research and best-practice. Benefit from our curated resources, publications, and educational programs designed to enhance your skills, expand your knowledge, and foster professional development.

For more information and to join, scan the QR code or head to our website



WWW.APSAD.ORG.AU

SAVE THE DATE

27-30 OCTOBER 2024

APSAD SCIENTIFIC DRUG AND
ALCOHOL CONFERENCE CANBERRA

National Convention Centre, Canberra
apsadconference.com.au



APSAD
CANBERRA 2024